RECRUITING

Study of BHV-1300 in Graves' Disease

Description

The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.

Conditions

Graves Disease
Talk to us

Related Conditions:

Graves Disease

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.

An Open-Label Biomarker Study of BHV-1300 in Graves' Disease

Study of BHV-1300 in Graves' Disease

Condition
Graves Disease
Intervention / Treatment

-

Contacts and Locations

South Gate

Site-103, South Gate, California, United States, 90280

Miami

Site-100, Miami, Florida, United States, 33126

Columbus

Site-104, Columbus, Georgia, United States, 31904

Houston

Site-101, Houston, Texas, United States, 77095

Shavano Park

Site-105, Shavano Park, Texas, United States, 78231

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit.
  • 2. History of treatment with radioactive iodine or thyroid surgery.

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Biohaven Therapeutics Ltd.,

Study Record Dates

2026-03